The constant emergence of resistance to classical antibiotics imposes to find new molecules. AMPs are naturally harder to develop resistance against, meaning that our drugs will be there for the long run.
Bringing the most advanced AI technology to biopharma
Less than 1 % of drug discovery projects usually lead to a marketted drug.
We use cutting-edge chemical language to link the structure and activity of our molecules, within a virtually unlimited chemical space. Therefore, contrarily to traditional drug discovery, which looks for a needle in a haystack, Sepia efficiently generates the best drug candidates, like a huge magnet in a gigantic hay field.
Each round of tests furthermore fine-tunes our machine learning model, which only gets better at creating de novo peptides as time goes by.
This continuous augmentation will allow us to scale efficiently, accelerating the development of new treatments and improving patient outcomes globally. Our approach ensures that we stay at the forefront of innovation, continually adapting to meet the ever-evolving challenges in biopharma.
Building a robust TechBio platform
By using the latest peptide synthesizers and bringing in the most talented experts, Sepia will ensure a sturdy debit of precisely-tailored molecules.
Our integrated platform will combine state-of-the-art technology with deep scientific expertise, enabling us to rapidly iterate and optimize our drug candidates. This approach not only enhances the efficiency of our discovery process but also increases the likelihood of successful clinical outcomes. As we continue to innovate and expand our capabilities, Sepia is poised to make significant contributions to the future of personalized medicine and advanced therapeutics.
Increasing success rates in clinical trials
Once designed and synthesized, our peptides are rigorously evaluated through in vivo tests.
Traditionally, 90% of drug candidates fail to reach the market. And while peptides are a promising new class of drugs, some of these molecules have shown lower stability in physiological environments. Sepia’s advanced AI generates peptide sequences with a high probability of bioactivity, with sturdy biostability.
As a result, while not significantly reducing the number of necessary in vivo experiments, our optimized lead candidates will demonstrate improved success rates in later clinical trials. This efficiency translates to significant time and cost savings, paving the way for more effective treatments to reach patients faster.
Cost reduction
foreseen in
drug development
Your investment is pivotal in advancing our mission. We seek partners who share our commitment to innovation, integrity, and impact. Together, we can drive positive change in healthcare by scaling our technology to new heights. Join us in shaping the future of medicine.
TechBio isn’t just a buzzword – it’s the heart of what we do at Sepia. Unlike traditional biotech, which often focuses solely on biological processes, TechBio marries cutting-edge technology with the intricacies of life sciences to push the boundaries of innovation even further. It’s where state-of-the-art algorithms meet the complexities of biology, where data drives discovery, and where innovation knows no bounds. At Sepia, we’re pioneers in this exciting field, leveraging the latest in AI, machine learning, and computational modeling to accelerate drug development, customize treatments, and revolutionize patient care. Step into the future of medicine with Sepia and experience the transformative potential of TechBio firsthand!
Antibiotic resistance, the ability of bacteria to evolve and withstand the effects of antibiotics, poses a critical threat to global health.
Today, it causes more than a million deaths each year, and will bring about 90 trillion $ in related costs by 2050 if we maintain the current trend.
The rise of multidrug-resistant bacteria, such as the notorious ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), complicates treatment options and increases the risk of deadly infections. Without effective antibiotics, common medical procedures such as surgeries, chemotherapy, and organ transplants become perilous endeavors.
At Sepia, we’re dedicated to combating antibiotic resistance by pioneering innovative solutions that target resistant bacteria through the efficacy of our antimicrobial peptides. Join us in the fight against antibiotic resistance and safeguard the future of global health.
Sepia, a burgeoning startup nestled in France’s coastal gem of Brest, draws inspiration from the enigmatic cuttlefish. Much like this remarkable creature and its w-shaped eye, renowned for its keen perception and adaptability, Sepia aims to broaden the horizons of medical innovation. Just as the cuttlefish’s ink serves as a mysterious reservoir of knowledge, our namesake serves as the foundation of our machine learning endeavors. Much like the creature’s tentacles, our technology intricately navigates the vast sea of peptides, precisely targeting and harnessing their therapeutic potential.
© 2024 Sepia
